Heat Biologics, Inc. Reports 2014 Third Quarter Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Heat Biologics, Inc. Reports 2014 Third Quarter Financial Results

DURHAM, N.C., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX ), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today its financial results for the third quarter ended September 30, 2014 and outlined key highlights of its lead clinical development programs.

THIRD QUARTER AND RECENT CLINICAL DEVELOPMENT HIGHLIGHTS:

Vesigenurtacel-L (HS-410) for the treatment of bladder cancer

  • Completed enrollment in the Phase 1 portion of the Phase 1/2 clinical trial.
  • Initiated patient enrollment and dosing in Phase 2 bladder cancer study in October 2014. This trial is expected to be fully enrolled in the third quarter of 2015; topline one-year recurrence-free survival results are expected to be reported by the third quarter of 2016.

Viagenpumatucel-L (HS-110) for the treatment of non-small cell lung cancer

  • Initiated patient dosing in Phase 2 lung cancer study. Interim immune response from the first 14 patients expected to be reported in the first half of 2015. The protocol of this trial is designed to demonstrate improved overall survival with combination immunotherapy.

Third Quarter 2014 Financial Highlights

  • R&D expenses were relatively flat at $1.0 million for the third quarter ended September 30, 2014 compared with the third quarter ended September 30, 2013.
  • Clinical and regulatory expenses were $1.3 million for the third quarter ended September 30, 2014, compared with $0.2 million for the third quarter ended September 30, 2013.
  • General and administrative (G&A) expenses were $0.8 million for the third quarter ended September 30, 2014, compared with $0.7 million for the third quarter ended September 30, 2013.
  • Net loss attributable to common stockholders was $3.0 million, or $0.46 per share for the third quarter ended September 30, 2014, compared with a net loss attributable to common stockholders of $2.3 million, or $0.48 per share, for the third quarter ended September 30, 2013.
  • Cash, cash equivalents and short-term investments were $15.4 million at September 30, 2014.

"We continue to make excellent progress in advancing our novel drug candidates," stated Jeff Wolf, CEO of Heat Biologics. "We reached important milestones with the initiation of patient dosing in Phase 2 trials for both lung and bladder cancer. Both are areas where we believe our products can address significant unmet medical needs. We note that the start of the bladder trial was achieved a full quarter earlier than anticipated, which should allow us to provide our disease-free survival data ahead of schedule."

THIRD QUARTER 2014 FINANCIALS:

At September 30, 2014, cash and cash equivalents and short-term investments totaled $15.4 million. Based on Management's projections, the Company's existing cash and short-term investments are anticipated to continue to fund operations for at least the next 12 months. 

For the third quarter ended September 30, 2014, Heat Biologics reported a net loss of $3.1 million and a net loss attributable to common stockholders of $3.0 million, or $0.46 per share. This compared with a net loss of $2.0 million, and a net loss attributable to common stockholders of $2.3 million, or $0.48 per share, for the third quarter ended September 30, 2013. The widened loss was primarily attributable to increased R&D, clinical and regulatory and G&A expenses.

R&D spending in the third quarter compared to a year ago was relatively flat at $1.0 million. Higher compensation costs and costs associated with establishing the Durham, NC facility were offset by lower patent, licensing and pre-manufacturing costs, as well as lower consulting fees.

Clinical and Regulatory expenses were $1.3 million, compared with $0.2 million for the quarter ending September 30, 2013, due to increases in clinical trial execution costs, manufacturing and drug handling costs related to the production of vaccines, as well as personnel, travel and facilities costs. The increase was offset primarily by lower consulting costs as well as decreases in various other expenses.

G&A expenses rose 14% to $0.8 million from $0.7 million, due primarily to increased costs associated with operating as a public company, increased personnel, franchise tax and travel costs. These increased costs were offset by lower consulting, and miscellaneous administrative costs.

About Heat Biologics, Inc. 

Heat Biologics, Inc. ( www.heatbio.com ) is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf"  ImPACT  therapeutic vaccines to combat a wide range of cancers. Our  ImPACT  Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat is conducting a Phase 2 trial of its viagenpumatucel-L ( HS-110 ) in patients with non-small cell lung cancer as well as a Phase 2 with its vesigenurtacel-L ( HS-410 ) in patients with non-muscle invasive bladder cancer.

Forward Looking Statements

This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the expected timing of full enrollment of the Vesigenurtacel-L (HS-410) Phase 2 trial, the expected timing of release of top line results of the Vesigenurtacel-L (HS-410) Phase 2 trial, the expected timing of the reporting of the interim immune response from the first 14 patients of the Viagenpumatucel-L (HS-110) Phase 2 clinical trial and the potential for Heat's  ImPACT  Therapy. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability for Heat's  ImPACT  Therapy to perform as designed and ability to enroll patients as planned and the other factors described in our annual report on Form 10-K for the year ended December 31, 2013 and our other filings with the SEC. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

HEAT BIOLOGICS, INC.
Condensed Consolidated Statements of Operations
(unaudited)
         
  Three Months Ended, Nine months Ended
  September 30, September 30,
  2014 2013 2014 2013
Operating expenses:        
Research and development 1,025,442 992,360 2,425,404 2,121,628
Clinical and regulatory 1,258,566 230,924 3,218,137 747,915
General and administrative 832,101 737,540 2,844,883 1,443,856
Total operating expenses 3,116,109 1,960,824 8,488,424 4,313,399
         
Loss from operations (3,116,109) (1,960,824) (8,488,424) (4,313,399)
         
Total non-operating income (expense) (11,160) (68,368) (20,168) (178,469)
         
Net loss (3,127,269) (2,029,192) (8,508,592) (4,491,868)
         
Net loss - non-controlling interest (126,865) (61,750) (330,675) (139,796)
Beneficial conversion charge — — — (2,300,000)
Preferred stock dividend — (361,668) — (361,668)
Net loss attributable to common stockholders (3,000,404) (2,329,110) (8,177,917) (7,013,740)
         
Net loss per share attributable to common stockholders—basic and diluted  $ (0.46)  $ (0.48)  $ (1.27)  $ (2.45)
         
Weighted-average number of common shares used in net loss per share attributable to common stockholders—basic and diluted 6,469,272 4,835,582 6,445,129 2,863,310
     
HEAT BIOLOGICS, INC.
Condensed Consolidated Balance Sheets
     
  September 30, December 31,
  2014 2013
  (unaudited)  
Assets    
     
Current Assets    
Cash and cash equivalents  $ 3,281,984  $ 4,566,992
Short-term investments 12,115,118 17,297,165
Related party receivable 43,392 24,946
Prepaid expenses and other current assets 648,363 1,066,638
Total Current Assets 16,088,857 22,955,741
     
Property and Equipment, net 464,348 53,753
     
Total Other Assets 183,455 10,572
     
Total Assets  $ 16,736,660  $ 23,020,066
     
Liabilities and Stockholders' Equity    
     
Current Liabilities    
Accounts payable  $ 680,478  $ 651,917
Accrued expenses and other payables 446,162 503,050
Accrued interest — 25,364
Current portion of long term debt 130,041  —
Total Current Liabilities 1,256,681 1,180,331
     
Long Term Liabilities    
Long-term debt, net 1,058,475 —
Stock warrants liability — 122,590
Total Liabilities 2,315,156 1,302,921
     
Total Stockholders' Equity– Less Non-Controlling Interest 15,026,956 21,991,922
Non-Controlling Interest (605,452) (274,777)
Total Stockholders' Equity 14,421,504 21,717,145
     
Total Liabilities and Stockholders' Equity  $ 16,736,660  $ 23,020,066

Heat Biologics, Inc. Contact Information: Matthew Czajkowski Chief Financial Officer (919) 240-7133 Investor Relations Michael Wood LifeSci Advisors LLC (646) 597 6983

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Telit Cinterion Tests Its Defense Connectivity Pitch

Updated Category News Views 107

Defense connectivity is a messy business, and Telit Cinterion is leaning straight into the mess at NATO Edge 2026 in Izmir, Turkey. From November 17 through 19, the company is using Booth L86 to show how several wireless links can live inside one mission-focused setup. That may sound like standard trade-show wallpaper, but the underlying problem is very real: military and...

Continue Reading
Hyster-Yale's $125 Million Convertible Debt Shuffle

Updated Category News Views 86

Forklifts do not make headlines often, but debt terms sure can. Hyster-Yale has proposed a $125 million private offering of convertible senior notes due November 15, 2031, with buyers able to take another $18.75 million if the initial purchasers exercise their option. For NYSE:HY holders, this is not a victory lap or a distress flare by itself. It is a refinancing...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 45

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 121

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 20

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 164

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 112

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 38

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push

Updated Category News Views 95

A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...

Continue Reading

Top 5 Most Recently Viewed Articles

Shell PLC's Strategic Share Repurchase Program Explained

Updated Category News Views 198

Understanding Shell PLC's Share Repurchase Strategy Shell plc has recently made headlines with its ongoing share buyback program. On a notable date, the company announced a significant purchase of its own shares intended for cancellation. This action is a part of its broader strategy to enhance shareholder value and optimize its capital structure. Details of the Share...

Continue Reading
Teck Resources Faces Maintenance Challenges at Chile Operations

Updated Category News Views 255

Maintenance Updates from Teck Resources Limited Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) has recently reported important updates regarding maintenance challenges at its operations in Chile. A mechanical issue has emerged at the Carmen de Andacollo (CdA) site, necessitating a temporary shutdown of the SAG mill. According to the latest information,...

Continue Reading
Neinor Homes Achieves FY24 Targets and New Shareholder Returns

Updated Category News Views 151

Neinor Homes Achieves Fiscal Targets for 2024 In a recent update, Neinor Homes reports successful fulfillment of its Adjusted Net Income target of €65 million for fiscal year 2024. The company, known for its prominence in residential property development, is now poised for continued growth. With the expected announcement of its fiscal results set for the latter part of...

Continue Reading
STG Logistics Staff Earn Supply Chain Accolades

Updated Category News Views 41

There's a fresh breeze running through the corridors of STG Logistics. Why? Because two of their own have snagged some serious recognition with the 2026 Women in Supply Chain Awards. This isn't just another blip on the corporate radar—it's a salute to the powerhouse of leadership and innovation nestled within the company's ranks. Geoff Anderman, the CEO himself, was...

Continue Reading
WISeKey International Holding Ltd Unveils AGM Agenda for Stakeholders

Updated Category News Views 284

WISeKey International Holding Ltd Unveils AGM Agenda for Stakeholders WISeKey International Holding Ltd, recognized for its significant contributions in the fields of cybersecurity and IoT, has announced the essential items for consideration by its shareholders at the upcoming Annual General Meeting (AGM). This important gathering, set to foster engagement between...

Continue Reading